hackint0sh/New-Dataset huggingface dataset:
Preliminary findings show that the study of NLRP3 promoter methylation could be reduced in the blood of SRNS compared with steroid-sensitive nephrotic syndrome (SSNS) patients. Moreover, unpublished encouraging results on the association between Growth Arrest Specific 5 (GAS5) expression and steroid response in INS in PBMCs were obtained in a preliminary study conducted on 8 patients with the first episode of INS. PBMCs were obtained and GAS5 gene expression was evaluated using TaqMan technology. Patients affected with SRNS presented significantly higher levels of GAS5 in comparison with the SSNS group. In PBMCs from SRNS patients, the GAS5 expression could reduce the availability for binding to GCs target genes of the activated GCs receptor and suppresses GC transcriptional activity. conditions: Nephrotic Syndrome studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED name: Transcriptome analyses measure: Between groups differences in molecular signature by whole transcriptome analysis sex: ALL minimumAge: 1 Year maximumAge: 12 Years stdAges: CHILD facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" status: RECRUITING city: Trieste zip: 34137 country: Italy name: Marco Pennesi, MD role: CONTACT phone: +39.040-3785263 email: marco.pennesi@burlo.trieste.it name: Barbara Bonifacio role: CONTACT phone: +39.040.3785.422 email: barbara.bonifacio@burlo.trieste.it lat: 45.64953 lon: 13.77679 hasResults: False
nctId: NCT06325124 id: REC/01805 MARIA NAWAZ briefTitle: Muscle Energy Technique of Lower Limb Muscles in Forward Head Posture overallStatus: RECRUITING date: 2024-03-26 date: 2025-03-20 date: 2025-04-20 date: 2024-03-22 date: 2024-04-03 name: Riphah International University class: OTHER briefSummary: The aim of this randomized controlled trial is to find the effect of muscle energy technique of muscles involved in lower limb superficial backline (hamstring and Gastro-soleus) on improving craniovertebral angle and cervical proprioception and minimizing pain among patients with forward head posture conditions: Forward Head Posture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 36 type: ESTIMATED name: Muscle energy technique name: Conventional PT measure: Neck disability index (NDI) measure: Numeric Pain Rating Scale NPRS measure: Bubble inclinometer measure: FHP Mobile Application (To measure Craniovertebral angle) measure: Cervical Joint Position Error sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: We Care Physical Therapy Clinic street 13 phase 4A, Ghouri town Islamabad status: RECRUITING city: Islamabad state: Punjab country: Pakistan name: KINZA ANWAR, MS-OMPT role: CONTACT phone: +92-3239735427 email: kinza.anwar@riphah.edu.pk name: MARIA NAWAZ, MS-OMPT* role: CONTACT phone: +92-3435625466 name: MARIA NAWAZ role: SUB_INVESTIGATOR lat: 33.72148 lon: 73.04329 hasResults: False
nctId: NCT06325111 id: RC 06/2023 briefTitle: Determinants of Glycaemic Control in Children With Type 1 Diabetes overallStatus: RECRUITING date: 2023-05-29 date: 2026-04-30 date: 2026-04-30 date: 2024-03-22 date: 2024-03-22 name: IRCCS Burlo Garofolo class: OTHER briefSummary: Type 1 diabetes (T1D) is a common chronic disease of childhood associated with a significantly increased risk of micro- and macro-vascular complications, including neuropathy, nephropathy and cardiovascular diseases. The risk of development T1D comorbidities is associated with glycaemic control, a complex mechanism involving biological, physiological environmental factors.
While more than 60 genetic variants were already associated with Glycated hemoglobin (HbA1c) in healthy subjects, very few genes have been identified in T1D individuals. Also, hyperglycaemia could be the cause of epigenetic changes at specific target genes, such as DNA methylation, histone modifications and microRNAs, correlated to accelerated development of diabetes-related complications. Most recently, increasing evidence also suggested that human microbiome may play a crucial role in the onset and progression of T1D and dysbiosis of the gut and oral microbiota was reported as a typical feature of hyperglycaemia.
However, potential differences among poorly and good managed T1D subjects have not been still studied. Also, the exact mechanism by long-term hyperglycaemia's acts in T1D remains poorly understood. Therefore, this project will explore an emerging area of research by the study of possible genetic, epigenetic and environmental biomarkers among T1D subjects with different glycaemic control. conditions: Diabetes Mellitus, Type 1 studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 800 type: ESTIMATED name: Determinants of T1D glycaemic control measure: Identification of genes involved in T1D glycaemic control measure: Identification of DNA methylation patterns involved in T1D glycaemic control measure: Identification of microRNAs involved in T1D glycaemic control measure: Identification of oral microbiome characteristics associated to T1D glycaemic control sex: ALL minimumAge: 6 Years maximumAge: 20 Years stdAges: CHILD stdAges: ADULT facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" status: RECRUITING city: Trieste zip: 34137 country: Italy name: Eulalia Catamo, BSc role: CONTACT phone: +39 040.3785470 email: eulalia.catamo@burlo.trieste.it lat: 45.64953 lon: 13.77679 hasResults: False
nctId: NCT06325098 id: PER-NEPH briefTitle: Implementation of a Diagnostic Workflow for Personalized Diagnosis of Nephrotic Syndrome overallStatus: RECRUITING date: 2022-01-26 date: 2026-01-31 date: 2026-06-30 date: 2024-03-22 date: 2024-03-22 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Nephrotic syndrome (NS) is a clinical picture common to several diseases resulting from damage to podocytes and glomerular filtration barrier. Currently, there is limited consensus regarding the diagnostic pathway and management of the specific etiology. Some patients show complete response to first-line steroid therapy (steroid-sensitive nephrotic syndrome, SSNS), especially in children and young adults. The prognosis of this group is generally favorable. In contrast, patients unresponsive to steroids (steroid-resistant NS, SRNS) frequently undergo immunosuppressive therapies, which are burdened with numerous side effects. Resistance to treatment is associated with a high likelihood of progression to chronic renal disease (CKD) and kidney failure (ESKD). Recent evidence suggests that immunological mechanisms (including permeabilizing factors) are involved in the pathogenesis of post-transplant NS recurrence and SSNS.
Providing patients with NS with a correct diagnosis is the cornerstone of personalized medicine, reducing morbidity and side effects of therapies, ensuring their appropriate prescription, and slowing or preventing progression to ESKD. conditions: Nephrotic Syndrome studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients with nephrotic syndrome (SSNS, SRNS) primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: Anti-nephrin antibodies name: u-RPC cultures measure: Role of anti-nephrin antibodies in the pathogenesis of NS measure: Functional role of VUS in the pathogenesis of SRNS measure: Identification of potential predictive biomarkers of renal outcome. measure: Cost-effectiveness analysis sex: ALL minimumAge: 1 Month maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Paola Romagnani role: CONTACT lat: 43.77925 lon: 11.24626 hasResults: False
nctId: NCT06325085 id: Ayesha Saddiqa briefTitle: Compensatory and Restorative Rehabilitation Techniques in Stroke acronym: The overallStatus: RECRUITING date: 2024-04-16 date: 2025-03-20 date: 2025-04-20 date: 2024-03-22 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: The aim of this randomized controlled trial is to find the combined effects of restorative and compensatory cognitive rehabilitation techniques in mild cognitive impairment after stroke. conditions: Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 36 type: ESTIMATED name: compensatory and restorative rehabilitation techniques name: Traditional cognitive rehabilitation training measure: Montreal cognitive assessment test (Urdu version) measure: Cognitive assessment scale for stroke patients (CASP) measure: Stroke specific quality of life questionnaire (Urdu version) measure: Modified Rankin Scale (MRS) sex: ALL minimumAge: 50 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shafi Hospital Dina status: RECRUITING city: Dina state: Punjab country: Pakistan name: Dr. Aroosa Tariq, MS:NMPT role: CONTACT phone: 03161578156 email: aroosa.tariq@riphah.edu.pk name: Ayesha Saddiqa, MS:NMPT* role: CONTACT phone: 0315-5568417 email: aisha.sadeeqa23@gmail.com name: Dr. Aroosa Tariq, MS:NMPT role: PRINCIPAL_INVESTIGATOR name: Ayesha Saddiqa, MS:NMPT* role: SUB_INVESTIGATOR hasResults: False
nctId: NCT06325072 id: NIKE briefTitle: Set-up of a Platform for Personalized Diagnosis of Rare Kidney Diseases (NIKE) overallStatus: ACTIVE_NOT_RECRUITING date: 2021-07-09 date: 2023-06-27 date: 2024-06-30 date: 2024-03-22 date: 2024-03-22 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Chronic kidney disease (CKD) is a major health problem, with steadily increasing incidence and prevalence and the threat of a true "epidemic". Converging evidence suggests a high prevalence of genetic etiology in rare kidney diseases and the list of new disease-causing genes is constantly updated. Recent advances in next-generation sequencing (NGS) technologies have prompted a significant improvement in the diagnosis of rare kidney diseases. Notwithstanding this, NGS generates high numbers of information that need to be properly analysed by the joint efforts of geneticists, nephrologists and bioinformatics in order to integrate clinical and genetic information in a personalized manner. In addition, in selected cases, the contribution of researchers proves essential for the development of experimental models of the disease to study and understand the pathogenic features and propose a personalized therapeutic approach. Such an innovative, integrated diagnostic paradigm is currently available in few centers all over the world and cannot be easily translated in daily clinical practice.
The aim of the study is to set-up an integrated diagnostic algorithm to extend the newest personalized diagnostic and treatment strategies for rare kidney diseases to all patients in the Tuscany region, under 40 years of age with kidney disease. This algorithm will be based on a constant cross-talk between participating centers and a dedicated multidisciplinary team. Diagnostic and therapeutic performances will be validated at European level. conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients selected based on the inclusion criteria will be evaluated by a multidisciplinary team of experts. All the selected patients will undergo genetic testing by clinical exome sequencing and in silico filtering for a panel of genes described as causing or in association with CKD. Identified variants will be classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines. Reverse phenotyping will be performed according to the results of genetic testing. The results of the diagnostic work-up will be evaluated by a multi-disciplinary team of experts in order to establish conclusive diagnosis. primaryPurpose: DIAGNOSTIC masking: NONE count: 160 type: ESTIMATED name: Conclusive genetic testing name: Genotype-phenotype correlation for personalized diagnosis name: Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip measure: Validation of genetic diagnosis measure: Identification of molecular pathways measure: Explore the applicability of gene editing in rare kidney diseases sex: ALL maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Azienda Ospedaliero Universitaria Careggi city: Firenze country: Italy lat: 43.77925 lon: 11.24626 facility: Meyer Children's Hospital IRCCS city: Firenze country: Italy lat: 43.77925 lon: 11.24626 facility: USL Toscana Centro city: Firenze country: Italy lat: 43.77925 lon: 11.24626 facility: Azienda Ospedaliero Universitaria Pisana city: Pisa country: Italy lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06325059 id: BIO-KIDNEY briefTitle: The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases overallStatus: RECRUITING date: 2023-03-22 date: 2047-03-22 date: 2047-11-30 date: 2024-03-22 date: 2024-03-22 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Renal progenitors are a subset of parietal epithelial cells (PECs) localized at the urinary pole of Bowman's capsule. Experimental models of podocyte damage showed that PECs can potentially regenerate lost podocytes by migrating from Bowman's capsule to the glomerular tuft, acquiring the morphological and functional features of mature podocytes. Podocyte loss and damage, as well as the inability of PECs to replace lost podocytes, lead to glomerular scarring and chronic kidney disease (CKD) progression.
The rationale of this project is to study the role of renal progenitors (PECs and tubular progenitors) in the pathogenesis of CKD and AKI trough super resolution imaging applied to human renal biopsies, to the aim of identifying relevant connections with clinical data and markers of damage and/or disease progression. conditions: Nephropathy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients affected by nephropathy primaryPurpose: BASIC_SCIENCE masking: NONE count: 200 type: ESTIMATED name: Study of renal progenitors measure: Evaluation of the role of renal progenitors in the progression of glomerular diseases measure: Evaluation of the role of tubular endoreplication in mechanisms of acute kidney injury (AKI) measure: Evaluation of the role of tubular endoreplication in mechanisms of acute kidney injury (AKI) trough DNA and RNA analysis sex: ALL minimumAge: 1 Month maximumAge: 17 Years stdAges: CHILD facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Paola Romagnani role: CONTACT lat: 43.77925 lon: 11.24626 hasResults: False
nctId: NCT06325033 id: 18546 briefTitle: Prospective Validation of the Eleveld Model of Propofol for Procedural Sedation in Adults. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-01 date: 2025-01 date: 2024-03-22 date: 2024-03-22 name: University Medical Center Groningen class: OTHER briefSummary: The goal of this prospective observational study is to identify effect site concentrations (CET) of propofol using the Eleveld model for different levels of procedural sedation.
Participants vital signs will be monitored according to the departmental protocol. Sedation will be administered using Target-Controlled Infusion (TCI) of propofol (administered by effect-site TCI using the Eleveld model) and remifentanil (administered by effect site TCI using the Eleveld model). Target controlled infusion of propofol and remifentanil is according to the departmental protocol. The MOAAS score will be noted every 5 minutes or when the target effect site concentration of propofol is altered. Depth of sedation will also be monitored using a non-invasive BIS® monitor. conditions: Deep Sedation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 75 type: ESTIMATED measure: To identify effect-site target concentrations of propofol for the Eleveld model that are associated with moderate to deep sedation levels, MOAAS 3-1 and the associated BIS levels in adult patients. measure: Induction time measure: Recovery time measure: Adverse events sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-11-23 uploadDate: 2024-02-29T03:59 filename: Prot_000.pdf size: 454063 hasResults: False
nctId: NCT06325020 id: 337367 briefTitle: Objective Risk Assessment in Patients With Possible Anginal Chest Pain Using Leading Technology acronym: ORACLE overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-01 date: 2025-02-28 date: 2024-03-22 date: 2024-03-22 name: University of Edinburgh class: OTHER briefSummary: The ORACLE study is an observational cohort study designed to explore the feasibility of providing an assessment of chest pain for patients with suspected angina within one working day of referral to specialist services.
The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events. conditions: Angina, Stable conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: The assessment of patients with possible angina using the ORACLE pathway measure: Proportion of participants in whom a chest pain risk assessment is complete within one working day of referral. measure: Proportion of patients who can have their risk assessment completed in one, two or three or more working days from referral to service until completion of risk assessment. measure: Proportion of valid and interpretable point-of-care troponin tests measure: Proportion of personal electrocardiograms that are interpretable measure: Proportion of participants stratified as low, intermediate, or high risk using objective risk stratification. measure: Proportion of participants with and without a clinical diagnosis of angina stratified as low, intermediate, or high risk and according to triage status. measure: Proportion of participants with unscheduled Emergency Department attendance(s) at 3 months stratified as low, intermediate, or high risk and according to triage status. measure: Proportion of participants with cardiac death or non-fatal myocardial infarction at 3 months stratified as low, intermediate, or high risk and according to triage. measure: Proportion of participants reclassified as low, intermediate, or high risk using standard laboratory assays compared to point-of-care high-sensitivity cardiac troponin assay. measure: Proportion of participants reclassified as low, intermediate, or high risk using standard 12-lead compared to personal 12-lead electrocardiography sex: ALL minimumAge: 30 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06325007 id: 293-2024-HFH briefTitle: Castor Oil Ingestion and Balloon Catheter for Labor Induction in Nulliparous overallStatus: RECRUITING date: 2024-04-11 date: 2024-12-15 date: 2024-12-31 date: 2024-03-22 date: 2024-04-15 name: Holy Family Hospital, Nazareth, Israel class: OTHER briefSummary: The goal of this randomized controlled trial is to examine the efficacy of combining castor oil ingestion with extra-amniotic single balloon catheter for cervical ripening on time from induction to delivery in nulliparous women.
Does the addition of the use of castor oil to extra-amniotic single balloon reduce the time until birth? Does the addition of the castor oil affect other perinatal outcomes during childbirth? Are the side effects of the castor tolerated by the mothers? Participants will be randomly divided into 2 groups: the study group will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, an extra-amniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. In the control group, a foley catheter will be inserted into cervical canal without ingestion of castor oil. conditions: Induction of Labor Affected Fetus / Newborn studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 142 type: ESTIMATED name: Induction of labor measure: time to delivery measure: balloon expulsion time measure: Bishop score after catheter expulsion measure: Fetal presentation at the delivery measure: Duration of the active phase of labor measure: Duration of second stage measure: Mode of delivery measure: Indications for cesarean or operative vaginal deliveries measure: Intrapartum fever measure: Number of patients that will require use of intrapartum use of antibiotic treatment. measure: Number of Participants with that will develop clinical signs of chorioamnionitis. measure: Number of Participants with that will develop 3rd and 4th degrees perineal lacerations. measure: Number of Participants with develop postpartrum hemorrhage. measure: Number of Participants with need blood transfusion. measure: Side effects related to castor oil use measure: Oxytocin maximal dosage measure: Number of participants with Umbilical Cord prolapse. measure: Apgar score (0 to 10). measure: pH taken from umbilical artery measure: Neonatal birthweight measure: Number of neonates with Neonatal fever ≥ 38 °C measure: The number of neonates that will develop neonatal sepsis. measure: The number of neonates that will require antibiotic treatment. measure: Neonatal complications measure: The number of neonates that will Admit to neonatal intensive care unit (NICU) measure: Length of stay in NICU. measure: neonatal death measure: Maternal hemoglobin level after delivery. measure: Number of participants that will require postpartum hysterectomy. measure: Number of participants that will require postpartum laparotomy. measure: postpartum maternal complications measure: The length of stay from birth to discharge home. measure: Maternal satisfaction from delivery process. sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Holy Family hospital, Nazareth status: NOT_YET_RECRUITING city: Nazareth country: Israel name: Wiaamk Khatib, MD role: CONTACT phone: 0549192433 email: wiaam.khatib.95@gmail.com name: Wiaam Khatib, MD role: PRINCIPAL_INVESTIGATOR lat: 32.69925 lon: 35.30483 facility: Holy Family Hospital status: RECRUITING city: Nazareth country: Israel name: Raed Salim, MD role: CONTACT email: r.salim@hfhosp.org lat: 32.69925 lon: 35.30483 hasResults: False
nctId: NCT06324994 id: YY-20394-BV-MCL briefTitle: Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-12-01 date: 2024-03-22 date: 2024-03-22 name: Dalian Medical University class: OTHER briefSummary: This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free triple therapy of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in R/R BV-MCL patients. conditions: Mantle Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Linperlisib in combination with Obinutuzumab and Venetoclax measure: Objective Response Rate (ORR) according to the RECIST 1.1 measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Duration of Overall Response (DOR) measure: Adverse event (AE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Hospital Dalian Medical University city: Dalian state: Liaoning zip: 116000 country: China name: Xiuhua Sun, Doctor role: CONTACT phone: +86 17709873631 email: 3038668@vip.sina.com lat: 38.91222 lon: 121.60222 hasResults: False